Re-examining the Nature and Function of Self-Reactive T cells

Trends in Immunology

Volumn 37, Issue 2, 2016, Pages 114-125

  Richards, David M ^a,b   Kyewski, Bruno ^a   Feuerer, Markus ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b APOGENIX GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD1C ANTIGEN; CD5 ANTIGEN; CRE RECOMBINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; T6 ANTIGEN; TETRAMER; TISSUE ANTIGEN; TRANSCRIPTION FACTOR FOXP3; AUTOANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENVIRONMENTAL CHANGE; GENE SEQUENCE; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SELF REACTIVE T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS; ANIMAL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; HUMANS; PERIPHERAL TOLERANCE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84983134471     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.12.005     Document Type: Review

References (81)

1. 1 Hogquist, K.A., Jameson, S.C., The self-obsession of T cells: how TCR signaling thresholds affect fate ‘decisions’ and effector function. Nat. Immunol. 15 (2014), 815–823.
2. 2 Klein, L., et al. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat. Rev. Immunol. 14 (2014), 377–391.
3. 3 Stritesky, G.L., et al. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30 (2012), 95–114.
4. 4 Mueller, D.L., Mechanisms maintaining peripheral tolerance. Nat. Immunol. 11 (2010), 21–27.
5. 5 Ota, K., et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990), 183–187.
6. 6 Rosenblum, M.D., et al. Mechanisms of human autoimmunity. J. Clin. Invest. 125 (2015), 2228–2233.
7. 7 Ito, Y., et al. Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science 346 (2014), 363–368.
8. + T cells with an anergic phenotype in healthy individuals. Science 346 (2014), 1536–1540.
9. + T lymphocytes. Immunity 42 (2015), 929–941.
10. + memory-phenotype T cells are abundant in unexposed adults. Immunity 38 (2013), 373–383.
11. 11 Jenkins, M.K., Moon, J.J., The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J. Immunol. 188 (2012), 4135–4140.
12. + T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 206 (2009), 849–866.
13. + T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27 (2007), 203–213.
14. 14 de Jong, A., et al. CD1a-autoreactive T cells are a normal component of the human αβ T cell repertoire. Nat. Immunol. 11 (2010), 1102–1109.
15. 15 de Lalla, C., et al. High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells. Eur. J. Immunol. 41 (2011), 602–610.
16. 16 Taylor, J.J., et al. Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen. J. Exp. Med. 209 (2012), 2065–2077.
17. 17 Meffre, E., Wardemann, H., B-cell tolerance checkpoints in health and autoimmunity. Curr. Opin. Immunol. 20 (2008), 632–638.
18. 18 Kim, J.M., et al. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8 (2007), 191–197.
19. + T-cell responses. Eur. J. Immunol. 44 (2014), 3621–3631.
20. 20 Richards, D.M., et al. The contained self-reactive peripheral T cell repertoire: size, diversity, and cellular composition. J. Immunol. 195 (2015), 2067–2079.
21. 21 Suchin, E.J., et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166 (2001), 973–981.
22. 22 Li, H.M., et al. The structural basis of T cell activation by superantigens. Annu. Rev. Immunol. 17 (1999), 435–466.
23. 23 Waterhouse, P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995), 985–988.
24. 24 Marie, J.C., et al. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 25 (2006), 441–454.
25. + T cell tolerance to tissue-restricted self-antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity 43 (2015), 896–908.
26. 26 Zehn, D., Bevan, M.J., T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25 (2006), 261–270.
27. + T cells. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 14602–14607.
28. 28 Enouz, S., et al. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J. Exp. Med. 209 (2012), 1769–1779.
29. + T cells specifically regulate the frequency of individual antigen-reactive T cells. Immunity 37 (2012), 735–746.
30. 30 Nelson, R.W., et al. T cell receptor cross-reactivity between similar foreign and self-peptides influences naive cell population size and autoimmunity. Immunity 42 (2015), 95–107.
31. 31 Birnbaum, M.E., et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157 (2014), 1073–1087.
32. + T cells. J. Immunol. 194 (2015), 2531–2538.
33. 33 Wooldridge, L., et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 287 (2012), 1168–1177.
34. 34 McDonald, B.D., et al. Crossreactive αβ T cell receptors are the predominant targets of thymocyte negative selection. Immunity 43 (2015), 859–869.
35. 35 Grossman, Z., Paul, W.E., Dynamic tuning of lymphocytes: physiological basis, mechanisms, and function. Annu. Rev. Immunol. 33 (2015), 677–713.
36. + T cells without selection of higher affinity TCR. Nat. Immunol. 2 (2001), 711–717.
37. + T cell sensitivity and response to a pathogen are set and sustained by avidity for thymic and peripheral complexes of self-peptide and MHC. Nat. Immunol. 15 (2014), 266–274.
38. 38 Mandl, J.N., et al. T cell-positive selection uses self-ligand binding strength to optimize repertoire recognition of foreign antigens. Immunity 38 (2013), 263–274.
39. + T cells to respond to foreign antigens. Nat. Immunol. 16 (2015), 107–117.
40. 40 Koehli, S., et al. Optimal T-cell receptor affinity for inducing autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 17248–17253.
41. 41 Henderson, J.G., et al. CD5 instructs extrathymic regulatory T cell development in response to self and tolerizing antigens. Immunity 42 (2015), 471–483.
42. 42 Moran, A.E., et al. T cell receptor signal strength in T-reg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208 (2011), 1279–1289.
43. 43 Stritesky, G.L., et al. Murine thymic selection quantified using a unique method to capture deleted T cells. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 4679–4684.
44. 44 Au-Yeung, B.B., et al. A sharp T-cell antigen receptor signaling threshold for T-cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E3679–E3688.
45. 45 Wolfl, M., et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181 (2008), 6435–6446.
46. 46 Stefanova, I., et al. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420 (2002), 429–434.
47. 47 Blank, M., et al. Molecular mimicry and auto-immunity. Clin. Rev. Allergy Immunol. 32 (2007), 111–118.
48. 48 Horai, R., et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity 43 (2015), 343–353.
49. 49 Baruch, K., Schwartz, M., CNS-specific T cells shape brain function via the choroid plexus. Brain Behav. Immun. 34 (2013), 11–16.
50. 50 Kipnis, J., et al. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 12 (2012), 662–668.
51. 51 Schwartz, M., Raposo, C., Protective autoimmunity: a unifying model for the immune network involved in CNS repair. Neuroscientist 20 (2014), 343–358.
52. 52 Moalem, G., et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5 (1999), 49–55.
53. 53 Zamvil, S.S., Steinman, L., The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8 (1990), 579–621.
54. + T cells. Blood 105 (2005), 1484–1491.
55. 55 Toulon, A., et al. A role for human skin-resident T cells in wound healing. J. Exp. Med. 206 (2009), 743–750.
56. 56 Feuerer, M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15 (2009), 930–939.
57. 57 Cipolletta, D., et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486 (2012), 549–553.
58. 58 Burzyn, D., et al. A special population of regulatory T cells potentiates muscle repair. Cell 155 (2013), 1282–1295.
59. 59 Arpaia, N., et al. A distinct function of regulatory T cells in tissue protection. Cell 162 (2015), 1078–1089.
60. 60 Elkon, K., Casali, P., Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4 (2008), 491–498.
61. 61 Kaveri, S.V., et al. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J. Immunol. 188 (2012), 939–945.
62. 62 Hsieh, C.S., et al. Selection of regulatory T cells in the thymus. Nat. Rev. Immunol. 12 (2012), 157–167.
63. 63 Perry, J.S., et al. Distinct contributions of Aire and antigen-presenting-cell subsets to the generation of self-tolerance in the thymus. Immunity 41 (2014), 414–426.
64. + regulatory T cells in the NOD mouse model of autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 18181–18186.
65. 65 Ohkura, N., et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37 (2012), 785–799.
66. 66 Delacher, M., et al. Transcriptional control of regulatory T cells. Curr. Top. Microbiol. Immunol. 381 (2014), 83–124.
67. 67 Yang, S., et al. Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance. Science 348 (2015), 589–594.
68. 68 Scharschmidt, T.C., et al. A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes. Immunity 43 (2015), 1011–1021.
69. 69 Kolodin, D., et al. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab. 21 (2015), 543–557.
70. 70 Hodi, F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
71. 71 Topalian, S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
72. 72 Wolchok, J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
73. 73 Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
74. 74 Melero, I., et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15 (2015), 457–472.
75. 75 Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
76. 76 Littman, D.R., Releasing the brakes on cancer immunotherapy. Cell 162 (2015), 1186–1190.
77. 77 Medler, T.R., et al. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer 1 (2015), 66–75.
78. 78 Kong, Y.C., Flynn, J.C., Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front. Immunol., 5, 2014, 206.
79. 79 Josefowicz, S.Z., et al. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30 (2012), 531–564.
80. 80 Klatzmann, D., Abbas, A.K., The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15 (2015), 283–294.
81. 81 Mathis, D., Benoist, C., Aire. Annu. Rev. Immunol. 27 (2009), 287–312.